TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.

MLA

Yung-Jue Bang, et al. “TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-Randomized Phase 1 Study.” Cancer Research & Treatment, vol. 50, no. 2, Apr. 2018, pp. 398–404. EBSCOhost, https://doi.org/10.4143/crt.2017.074.

APA

Yung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, & Toshihiko Doi. (2018). TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study. Cancer Research & Treatment, 50(2), 398–404. https://doi.org/10.4143/crt.2017.074

Chicago

Yung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, and Toshihiko Doi. 2018. “TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-Randomized Phase 1 Study.” Cancer Research & Treatment 50 (2): 398–404. doi:10.4143/crt.2017.074.